Built from a frustration I couldn't ignore.

Where this started.

My wife lives with chronic illness. I've been fortunate — I've never dealt with serious illness myself. But I've watched her be dismissed by providers, talked over, told her symptoms aren't that bad. The appointments that end without answers, the tests that come back normal, the quiet dismissals that accumulate over years of navigating a system not designed to handle ambiguity well.

That frustration is where Elpis started.

I'm a bioinformatics researcher. I build open-source tools for phylogenetics and genomics. I'm not a geneticist or a clinician. But I know how to find published research, evaluate the evidence, and present it in a way that's honest and accessible.

When I looked at what was available for people who already have data from 23andMe or AncestryDNA, I found two things: expensive reinterpretation services charging for what amounts to a text file lookup, and wellness companies wrapping weak evidence in flowery language to sell supplements. Confident-sounding reports with no citations. Companies treating genetic data as an asset to be monetized.

People need someone to sit down, look at the actual published studies, and say: here's what the research found, here's how strong the evidence is, here's what it can and cannot tell you, and here are the questions to bring to your doctor. That's what Elpis does. Nothing more, nothing less.

How Elpis is structured.

Elpis Biosciences LLC runs two divisions, in a deliberate relationship to one another.

The second funds the first.

That's the whole business model. No investors, no venture capital, and no path where user genetic data becomes an asset on a balance sheet — because there is no balance sheet it could sit on. The consumer reports cost us time, not revenue, and the services work covers the time.

What we believe.

What we are not.

Where this is going.

Elpis's current reports are Research Use Only — educational tools that give you better questions to bring to your provider, not answers to act on alone. That's not a hedge; it's an accurate description of what chip-based genotyping can support.

The longer-term goal is diagnostic-grade: tools specific and robust enough to be taken to a healthcare provider and acted on with confidence. That requires more data, regulatory clarity, and time. The free parser is the foundation of that trust — we want to earn the right to build the harder thing by doing this simpler thing well.

We watched 23andMe enter bankruptcy proceedings with millions of people's genetic data as a line item on a balance sheet. The technology was genuinely impressive. The failure was in treating user data as an asset rather than a trust. Elpis is built against that from the ground up.

This is version one. We're building in the open, and we're building it with you.